Teva reported positive topline results in a celiac disease gluten challenge study, saying its experimental antibody significantly reduced intestinal damage after patients consumed gluten for eight weeks. The company described the outcome as statistically significant and clinically meaningful versus placebo. With no FDA-approved drugs for celiac disease, the results place Teva’s TEV-408 in a competitive race that uses serologic and histologic readouts tied to gluten-driven immune activation. Teva said it is evaluating additional data from an ongoing Phase 2a program and plans to present further results at an upcoming scientific meeting. The update strengthens Teva’s autoimmune pipeline narrative by converting a traditionally difficult autoimmune target into a data-backed, trial-tested approach for a defined patient behavior model—gluten ingestion during the challenge period.